Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.

Literature DB >> 18986702

Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.

Walid Rasheed, Brendan Flaim, John F Seymour.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2008 PMID： 18986702 DOI： 10.1016/j.leukres.2008.09.026

Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156

Keyword Cloud
Cited

× No keyword cloud information.

24 in total

Review 1. Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors: James Hester; Corey Ventetuolo; Tim Lahm
Journal: Compr Physiol Date: 2019-12-18 Impact factor: 9.090

2. Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.

Authors: J-C Kim; S-H Shin; H G Yi; S-H Kim; S-I Woo; D-H Kim; K-S Park; J Kwan
Journal: Herz Date: 2013-02-23 Impact factor: 1.443

Review 3. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2.

Authors: Hui-Ming Chang; Tochukwu M Okwuosa; Tiziano Scarabelli; Rohit Moudgil; Edward T H Yeh
Journal: J Am Coll Cardiol Date: 2017-11-14 Impact factor: 24.094

4. The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia.

Authors: Lucy C Fox; Katherine D Cummins; Ben Costello; David Yeung; Rebecca Cleary; Cecily Forsyth; Maciek Tatarczuch; Kate Burbury; Olga Motorna; Jake Shortt; Shaun Fleming; Andrew McQuillan; Anthony Schwarer; Rosemary Harrup; Amy Holmes; Sumita Ratnasingam; Kah-Lok Chan; Wei-Hsun Hsu; Asma Ashraf; Faye Putt; Andrew Grigg
Journal: Blood Adv Date: 2017-05-15

9. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.

Authors: Koung Jin Suh; Ji Yun Lee; Dong-Yeop Shin; Youngil Koh; Soo-Mee Bang; Sung-Soo Yoon; Seonyang Park; Inho Kim; Jeong-Ok Lee
Journal: Int J Hematol Date: 2017-04-04 Impact factor: 2.490

Review 10. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

Authors: Elias Jabbour; Jeffrey H Lipton
Journal: Clin Lymphoma Myeloma Leuk Date: 2013-10-01

Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.

Review 1. Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

2. Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.

Review 3. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2.

4. The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia.

Review 5. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.

Review 6. Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword.

Review 7. Dasatinib-induced pulmonary arterial hypertension.

8. Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia.

9. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.

Review 10. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.